Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week [Yahoo! Finance]
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Ocular Therapeutix, Inc. (NASDAQ: OCUL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1 [Yahoo! Finance]